Nosocomial transmission of hepatitis E virus and development of chronic infection: The wider impact of COVID-19

https://doi.org/10.1016/j.jcv.2022.105083Get rights and content

Highlights

  • We describe an extremely rare hepatitis E virus (HEV) nosocomial transmission incident confirmed by molecular analysis.

  • This incident demonstrates the potential for HEV to be transmitted in a nosocomial setting under the exceptional circumstances created by the coronavirus disease 2019 (COVID-19) pandemic.

  • We highlight the potential impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its therapy on the natural course of HEV infection.

Abstract

Background

Transmission of hepatitis E virus (HEV) within the healthcare setting is extremely rare. Additionally, the development of chronic HEV infection in association with severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection and/or its immunomodulatory therapy has not been reported previously.

Aims

To describe the investigation and management of a nosocomial HEV transmission incident during the coronavirus disease 2019 (COVID-19) pandemic.

Methods

Epidemiological and molecular investigation of two individuals hospitalised with COVID-19 who were both diagnosed with HEV infection.

Results

Findings from our investigation were consistent with transmission of HEV from one patient with a community-acquired HEV infection to another individual (identical HEV sequences were identified in the two patients), most likely due to a breach in infection control practices whilst both patients shared a bed space on the intensive care unit (ICU). Chronic HEV infection requiring treatment with ribavirin developed in one patient with prolonged lymphopaenia attributable to COVID-19 and/or the immunomodulators received for its treatment. Further investigation did not identify transmission of HEV to any other patients or to healthcare workers.

Conclusions

The extraordinary demands that the COVID-19 pandemic has placed on all aspects of healthcare, particularly within ICU settings, has greatly challenged the ability to consistently maintain optimal infection prevention and control practices. Under the significant pressures of the COVID-19 pandemic a highly unusual nosocomial HEV transmission incident occurred complicated further by progression to a chronic HEV infection in one patient.

Keywords

HEV
Nosocomial
Hospital-acquired
Immunosuppressed
Tocilizumab

Cited by (0)

View Abstract